Can Natural Products Drug the Dark Proteome by Exploiting Uncharacterized Binding Sites, Structural Disorder, and Previously Untapped Protein Biology?

Download PDF

Large regions of the human proteome remain poorly developed as therapeutic targets, but limited chemical annotation, sparse functional knowledge, missing structures, and conformational heterogeneity should not be conflated with demonstrated undruggability. This conceptual article asks whether natural products can expand access to such "dark" protein space by exploiting recognition modes that conventional target-first discovery may undersample. The analysis separates several forms of darkness: missing biological evidence, absent or incomplete structural information, intrinsic disorder, transient or cryptic pockets, and insufficient target-validation tools. It then considers natural products not as intrinsically privileged dark-proteome ligands, but as chemically and biologically distinctive perturbagens whose complex scaffolds, stereochemistry, and phenotype-first discovery history may broaden the search for conditional protein recognition. A proposed framework links evidence-state classification, ensemble-aware structural reasoning, cryptic-site detection, natural-product prioritization, phenotypic discovery, chemoproteomic target deconvolution, and staged credibility testing. The central argument is that a protein should become more credible as a dark-proteome target only when computational plausibility is progressively replaced by orthogonal evidence of binding, cellular engagement, functional modulation, specificity, and mechanism. Important boundaries remain: predicted pockets are not measured pockets, binding is not mechanism, phenotypic activity may be polypharmacological or artifactual, and unusual chemistry does not establish privileged recognition. Natural products may therefore be most valuable as structured probes of unknown biology, provided uncertainty and falsification remain explicit. This strategy remains hypothesis-generating and requires target-specific experimental validation.